cbdMD, Inc. Announces Acceptance of Compliance Plan by NYSE AmericanAugust 26, 2024 4:25 PM EDT | Source: cbdMDCharlotte, North Carolina--(Newsfile Corp. - August 26, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBD-PA), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD, along with its functional mushroom brand ATRx Labs, today announced that it received notice from the NYSE American LLC that ...

财务数据和关键指标变化 - 总净销售额同比下降15%至5.1亿美元,但环比增长18% [22] - 电商直销业务销售额同比下降25%至3.9亿美元,但环比增长9% [22] - 毛利率提升至65%,高于上年同期的63% [24] - 销售管理费用同比下降33%至3.8亿美元 [25] - 经营亏损收窄至400万美元,上年同期为180万美元 [25] - 非公GAAP调整后经营亏损收窄至87万美元,上年同期为60万美元 [26] 各条业务线数据和关键指标变化 - 电商直销业务销售额占总销售额的76%,上年同期为82% [23] - 批发业务销售额同比增长10%至1.2亿美元 [23] 各个市场数据和关键指标变化 - 无具体披露 公司战略和发展方向及行业竞争 - 公司正专注于提高运营效率和盈利能力,实施了一系列成本控制措施 [10][11][12][34][35] - 公司认为CBD行业仍然充满挑战,存在一定的行业整合 [16] - 公司将继续保持警惕,特别关注快速变化的监管环境 [16] - 公司将专注于保持灵活性,并战略性地投入营销资金以确保可持续的盈利增长 [16] 管理层对经营环境和未来前景的评论 - 管理层对公司未来前景表示乐观,认为正在取得显著进展 [34][35] - 预计未来几个季度将实现更多成本节约,有望实现盈利 [33] - 公司将继续努力解决资本结构问题,以提升股东价值 [36] 其他重要信息 - 公司收到纽约证券交易所美国分部的通知,因净资产低于最低要求而面临退市风险 [20][21] - 公司已向纽约证券交易所提交了一项计划,希望在2025年12月前重新符合持续上市标准 [21] - 公司发布了一项人体临床试验结果,支持其产品在缓解疼痛、改善情绪和减轻压力方面的声明 [17][18][19] 问答环节重要的提问和回答 问题1 **Gene Schaefer 提问** 公司提交给纽约证券交易所的计划具体内容是什么 [39][40] **Ronan Kennedy 回答** 公司正在探索多种方式来稳定股东权益账面价值,包括向股东提出新的建议方案等 [40][41] 问题2 **Thomas McGovern 提问** 公司最近发布的临床试验结果具体情况如何 [47][48][49][50] **Ronan Kennedy 回答** 临床试验结果总体令人满意,但公司不希望过度强调这一研究,还需要通过其他方式向消费者传达产品价值 [49][50]

财务表现 - 公司总体销售额同比下降16%，但环比增长15.4%[161] - 电商销售占总销售额的76.1%，批发销售占23.9%[156] - 电商销售同比下降20%，批发销售同比增长10%[156,157] - 整体毛利率为65.8%，同比提升2.9个百分点[153] 成本优化 - 公司持续优化产品组合、精简成本结构、投资有效营销以实现盈利[140,147] - 公司通过多项成本优化措施每月节省开支超过20万美元[147] - 公司三个月和九个月期间的总运营费用分别下降了1.9百万美元和6.1百万美元，主要是由于管理层持续努力降低成本结构[168][167] 新品类和国际市场拓展 - 公司新品类如功能性蘑菇品牌ATRx在GNC渠道取得进展[143] - 公司正积极探索国际市场拓展机会，如南美洲等地区[150] 并购和资本结构优化 - 公司正评估潜在的并购机会以提升客户群和盈利能力[152] - 公司正努力简化资本结构以提升股权价值和推动战略发展[145] - 公司于2024年1月30日与五名投资者签订了证券购买协议，获得了125万美元的总收益[174] 持续经营风险 - 公司的营运资金可能不足以支持未来12个月的日常运营，存在持续经营的重大不确定性[176] 非GAAP财务指标 - 公司使用经调整EBITDA作为非GAAP财务指标来评估核心经营业绩[178][179][180][181] - 公司三个月和九个月的经调整EBITDA分别为-84,953美元和-1,549,701美元[183]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to _______________ Commission file number 001-38299 cbdMD, INC. (Exact Name of Registrant as Specified in its Charter) No ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to _______________ Commission file number 001-38299 cbdMD, INC. (Exact Name of Registrant as Specified in its Charter) ...

Non Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to __________ Commission file number 001-38299 cbdMD, INC. (Exact Name of Registrant as Specified in its Charter) North Carolina 4 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to _______________ Commission file number 001-38299 cbdMD, INC. (Exact Name of Registrant as Specified in its Charter) Nor ...

cbdMD, Inc. (NYSE:YCBD) Q2 2023 Earnings Conference Call May 15, 2023 4:15 PM ET Company Participants Brad Whitford - VP of Finance Ronan Kennedy - Interim Chief Executive Officer and Chief Financial Officer Sibyl Swift - Chief Science Officer & VP Regulatory Affairs Conference Call Participants Anthony Vendetti - Maxim Group Operator Good afternoon. Welcome to cbdMD's, Inc. March 31, 2023, Second Quarter of Fiscal '23 Earnings Call and Update. This afternoon, the company issued a press release that provide ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to _______________ Commission file number 001-38299 cbdMD, INC. (Exact Name of Registrant as Specified in its Charter) No ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to _______________ Commission file number 001-38299 cbdMD, INC. (Exact Name of Registrant as Specified in its Charter) ...